Class IITerminatedD-0003-2026
Drug recall · October 15, 2025
Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe recall
Why: Lack of assurance of sterility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.
- Lots / codes
Lot # 20250708-768A26, BUD: Oct 06, 2025 20250715-944DF2 BUD: Oct 13, 2025 20250722-55C603 BUD: Oct 20, 2025 20250722-5DC113 BUD: Oct 20, 2025
- Quantity
- 2,669 syringes
- Company
- RC Outsourcing, LLC, Lowellville, OH
- Distribution
- Nationwide in the US
- Initiated
- September 22, 2025 · Voluntary: Firm initiated
- Classified
- October 6, 2025
- Reported
- October 15, 2025
- Ended
- January 5, 2026
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.